Side-by-side comparison of AI visibility scores, market position, and capabilities
RTHM is a remote patient monitoring platform that uses wearable devices and AI to track chronic disease patients between clinical visits, enabling proactive care intervention. HQ: San Francisco.
RTHM is a remote patient monitoring (RPM) company providing technology and clinical services to help healthcare providers track patients with chronic conditions between office visits. The platform uses FDA-cleared wearable devices to continuously or periodically measure vital signs, symptoms, and disease-specific biomarkers, transmitting data to a clinical monitoring center where RTHM's care team reviews alerts and communicates with patients experiencing concerning trends before they escalate to emergency care.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.